The first patent, to expire in 2024, includes claims that more specifically define the components of the liquid formulation of NGX-1998. The second, set to expire in 2022, includes claims relating to methods for removing capsaicin from the body using a surfactant-free, polyethylene glycol gel.
“The two notices of allowance strengthen our U.S. patent estate for NGX-1998,” said Ronald Martell, president and CEO of NeurogesX. “Our Phase 2 data suggest that NGX-1998’s product profile, including a five-minute application for up to three months of pain relief, make it an exciting advance in pain therapy. We are continuing our efforts to move into Phase 3 clinical trials as expeditiously as possible.”
Related Articles on Pain Management:
Dr. Scott Glaser: 3 Concept in Interventional Pain Management to Reduce Hospitalization
Evolving Clinical Developments in Interventional Pain Management: The Mild Procedure
Nebraska Physician Group Opens Neuroscience Pain Clinic
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
